Dxxxx Xxxxx definition

Dxxxx Xxxxx. Name: Dxxxx Xxxxx Title: Chief Financial Officer SXXXXXX COMMUNICATIONS INC.

Dxxxx Xxxxx. Name: Dxxxx Xxxxx Title: Director BANK SXX. OXXXXXXXX JR. & CIE. (SWITZERLAND) By: “C. Xxxxxx” “B. Xxxxxxxxx Name: C. Xxxxxx B. Xxxxxxxxx Title: Director Comm. Mandatory Schedule 2.1 PURCHASERS AND COMMITMENT AMOUNTS Purchaser Number of Common Shares Commitment Amount ASSET PROTECTION FUND LTD. 215,703 $ 4,999,995.54 BANK SXX. OXXXXXXXX JR. & CIE. (SWITZERLAND) 215,703 $ 4,999,995.54 TOTAL 431,406 $ 9,999,991.08 Schedule 2.1 Exhibit A Form of Registration Rights Agreement [ATTACHED] FIRST AMENDMENT TO COMMON SHARE PURCHASE AGREEMENT This First Amendment to the Common Share Purchase Agreement (this “First Amendment”) is entered into and made effective on November 12, 2007, by and among INTEROIL CORPORATION (the “Company”), ASSET PROTECTION FUND LTD. and BANK SXX. OXXXXXXXX JR. & CIE. (SWITZERLAND) (the “Initial Purchasers”) and CLARION FINANZ A.G. (“Clarion”, and together with the Initial Purchasers, the “Purchasers”, each, “Purchaser”). The Company and each Purchaser are sometimes hereinafter referred to individually as a “party” and collectively as the “parties”.

Dxxxx Xxxxx. Name: Dxxxx Xxxxx Title: Director BANK SXX. OXXXXXXXX JR. & CIE. (SWITZERLAND) By: “C. Xxxxxx” “B. Xxxxxxxxx Name: C. Xxxxxx B. Xxxxxxxxx Title: Director Comm. Mandatory CLARION FINANZ A.G. By: “Cxxxx Xxxxxxx” Name: Cxxxx Xxxxxxx Title: Director Schedule 2.4 SUBSEQUENT PURCHASERS AND COMMITMENT AMOUNTS FOR SUBSEQUENT PLACEMENT ON THE SUBSEQUENT CLOSING DATE Subsequent Purchaser Number of Common Shares Commitment Amount ASSET PROTECTION FUND LTD. 323,554 $ 7,499,981.72 CLARION FINANZ A.G. 323,554 $ 7,499,981.72 TOTAL 647,108 $ 14,999,963.44 Schedule 2.4 Exhibit B Form of Amended and Restated Registration Rights Agreement AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amended and Restated Registration Rights Agreement (this “Agreement”) is entered into as of November 12, 2007, between INTEROIL CORPORATION, a Yukon Territory corporation (the “Company”) and the Purchasers set forth on the signature pages hereto (each, a “Purchaser” and collectively, the “Purchasers”).

Examples of Dxxxx Xxxxx in a sentence

• The Seller has no officers or any member or manager other than Dxxxx Xxxxx.

• All references in this Agreement to “knowledge of the Seller” shall mean the actual knowledge, after reasonable investigation, of the Seller and its sole manager, Dxxxx Xxxxx.

• Email: bxxx@xxxx.xxx If to the Company: Green Circle Decarbonize Technology Limited Uxxx 0000, Xxxxxxxxxx Xxxxx, 0 Xxxxx Xxx St. Kxxx Xxxx, Kxxxxxx, Hong Kong Attn: Email: With a copy (which shall not constitute notice) to: Nxxxx LPC 200 Xxxxx Xxxxxx Xxxx, Xxxxx 000, Toronto, Ontario M5V 0R2 Attn: Dxxxx Xxxxx, Esq.

• Xxxx Title: Vice President MXXXXXX LYNCH, PIERCE, FXXXXX & SXXXX INCORPORATED (in executing below agrees and becomes a party to the Terms Agreement set forth in Section D herein) By: /s/ Dxxxx Xxxxx Name: Dxxxx Xxxxx Title: Authorized Signatory INDEX OF EXHIBITS AND SCHEDULES TO THE OMNIBUS INSTRUMENT Exhibit A Standard Trust Terms — Incorporated herein by reference to Exhibit 99.2 to Principal Life Insurance Company’s Current Report on Form 8-K, filed on March 1, 2006.

• Any notice, demand, direction or instruction to be given to the Depositor, Evaluator or Supervisor hereunder shall be in writing and shall be duly given if mailed or delivered to the Depositor, 2455 Corporate West Dxxxx, Xxxxx, Xxxxxxxx 00000, xx xx xxxx xxxxx xxdress as shall be specified by the Depositor to the other parties hereto in writing.

• Dxxxx Xxxxx, with a copy to Bass, Bxxxx & Sxxx PLC, 100 Xxxxx Xxxxxx Xxxxx, Xxxxx 0000, Xxxxxxxxx, XX 00000, Attention: Lxxx X.

• Facsimile: 500-000-0000 If to Purchaser: Merck Global Health Innovation Fund, LLC Oxx Xxxxx Xxxxx Xxxxxxxxxx Xxxxxxx, Xxx Xxxxxx 00000-0000 Attn: Dxxxx Xxxxx Facsimile: 900 000-0000 With a copy to: MxXxxxxxx Will & Exxxx LLP 300 Xxxxxxx Xxxxxx Xxx Xxxx, XX 00000-0000 Attn: Txxx Finger, Esq.

• If to the Representative: EX Xxxxxx, division of Benchmark Investments, LLC 10 Xxxxxxx Xxxxx, Xxxxx 000 Xxx Xxxx, XX 00000 Attn: Dxxxx Xxxxx Email: dboral@EF Hxxxxxxx.xxx Copy (which copy shall not constitute notice) to: Ellenoff Gxxxxxxx & Schole LLP 1000 Xxxxxx xx xxx Xxxxxxxx Xxx Xxxx, Xxx Xxxx 00000 Attn: Bxxxx X.

• Xxxxx Title: Associate Director By: /s/ Dxxxx Xxxxx Name: Dxxxx X.

• Option Agreement dated as of June 13, 2003 by and among Mission Broadcasting, Inc., Dxxxx Xxxxx and Nexstar Broadcasting of Abilene, L.L.C.; expires June 13, 2012.

More Definitions of Dxxxx Xxxxx

Dxxxx Xxxxx. Name: Dxxxx Xxxxx Title: EVP, Corporate Development I have the authority to bind the corporation EPITOME GROUP HOLDINGS INC. Per: “Lxxxx Xxxxxxxx” Name: Lxxxx Xxxxxxxx Title: C.E.O. I have the authority to bind the corporation Per: “J. Sxxxxxx Xxxxx” Name: Sxxxxxx Xxxxx Title: President I have the authority to bind the corporation “J. Sxxxxxx Xxxxx” “Lxxxx Xxxxxxxx” Witness Lxxxx Xxxxxxxx SCHEDULE 1.1(p) – CLOSING DATE EXCESS CASH - see attached - Schedule 1.1 (p) Closing Date Excess Cash for the Purchased Entities April 3, 2014 Current Assets Cash Accounts receivable (net of allowance for doubtful accounts) Government remittances Prepaid expenses Total Current Assets (A) Current Liabilities Interim production financing Accounts payable & accrued liabilities Distribution payable Deferred revenues Income tax payable Other liabilities Total Current Liabilities (B) Sub-total (A-B) Adjustments: Current run-rate SG&A Bonus accrual Payroll accrual Total Adjustments ( C ) Closing Date Excess Cash (A-B+C) Notes:

Dxxxx Xxxxx. Name: Dxxxx Xxxxx Title: Chief Financial Officer CONCORDIA HEALTHCARE (CANADA) LIMITED Per: (signed) “Dxxxx Xxxxx” Name: Dxxxx Xxxxx Title: Director CONCORDIA INVESTMENTS (JERSEY) LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director CONCORDIA FINANCING (JERSEY) LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director CONCORDIA PHARMACEUTICALS INC., S.A R.X Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director CONCORDIA LABORATORIES INC., S.A R.X Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director AMDIPHARM HOLDINGS S.A R.X Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director AMDIPHARM AG Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director AMDIPHARM B.V. Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director AMDIPHARM LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director AMDIPHARM MERCURY HOLDCO UK LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director AMDIPHARM MERCURY UK LTD Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director CONCORDIA HOLDINGS (JERSEY) LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director AMDIPHARM MERCURY INTERNATIONAL LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director CONCORDIA INVESTMENT HOLDINGS (UK) LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director MERCURY PHARMA GROUP LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director CONCORDIA INTERNATIONAL RX (UK) LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director ABCUR AB Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director MERCURY PHARMACEUTICALS LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director FOCUS PHARMA HOLDINGS LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director FOCUS PHARMACEUTICALS LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director MERCURY PHARMA (GENERICS) LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director MERCURY PHARMACEUTICALS (IRELAND) LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director MERCURY PHARMA INTERNATIONAL LIMITED Per: (signed) “Axxxx Xxxxx” Name: Axxxx Xxxxx Title: Director STRICTLY CONFIDENTIAL Full Legal Name of Private Placement Party: [Redacted in accordance with Section 14 of this Agreement] Authorized Signature(s): [Redacted] Per: [Redacted] Name[Redacted] Title[Redacted]

Dxxxx Xxxxx. Name: Dxxxx X. Xxxxx Title: President and Chief Executive Officer KHNP CANADA ENERGY LTD. By: “Kxxxx-Xxx Xxxxx” Name: Kxxxx-Xxx Xxxxx Title: Director

Dxxxx Xxxxx. Dxxxx Xxxxx, Director Address: [Redacted - Personal Information] Multiple voting shares owned (beneficially or otherwise) as of the date hereof: 0 Subordinate voting shares owned (beneficially or otherwise) as of the date hereof: 0 Options held as of the date hereof: 0 RSUs/PSUs/DSUs held as of the date hereof: 21,369 (DSUs) [Signature page to the D&O Support and Voting Agreement] Accepted and agreed on this 1st day of April , 2024. NEON MAPLE PURCHASER INC. By: (signed) "Bxx Xxxxxx" Name: Bxx Xxxxxx Title: President [Signature page to the D&O Support and Voting Agreement]

Dxxxx Xxxxx s/ Per: /s/ “Gxxxx Xxxxxxxxxx” /s/